| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Revenue | $969K | +5.6% |
| Cost of Revenue | $229K | -56.5% |
| Gross Profit | $740K | +89.5% |
| R&D Expense | $1.3M | +83.6% |
| SG&A Expense | $6.7M | +33.3% |
| Operating Income | -$10.6M | -21.6% |
| Pre-tax Income | -$11.0M | -25.7% |
| Net Income | -$11.0M | -25.7% |
| EPS (Basic) | -$0.78 |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $87K | -81.6% |
| Accounts Receivable | $19K | -78.5% |
| Inventory | $390K | +5.3% |
| Current Assets | $1.0M | -26.8% |
| Total Assets | $3.1M | +27.7% |
| Current Liabilities | $1.4M | -2.8% |
| Total Liabilities | $2.4M | +41.7% |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.4M | -9.2% |
| Capital Expenditures | $309K | -27.1% |
| Investing Cash Flow | -$309K | +27.1% |
| Financing Cash Flow | $7.3M | +362.6% |
| Free Cash Flow | -$7.7M | -7.1% |
| +8.2% |
| EPS (Diluted) | -$0.78 | +8.2% |
| Stockholders' Equity |
| $686K |
| -5.4% |